Abstract |
Colorectal cancer (CRC) is among the leading causes of cancer-related death, principally due to its metastatic spread and multifactorial chemoresistance. The therapeutic failure can also be explained by inter- or intra- tumor genetic heterogeneity and tumor stromal content. Thus, the identification of novel prognostic biomarkers and therapeutic options are warranted in the management of CRC patients. There are data showing that microRNA-21 is elevated in different types of cancer, particularly colon adenocarcinoma and that this is association with a poor prognosis. This suggests that microRNA-21 may be of value as a potential therapeutic target. Furthermore, locked nucleic acid (LNA)-modified oligonucleotides have recently emerged as a therapeutic option for targeting dysregulated miRNAs in cancer therapy, through antisense-based gene silencing. Further work is required to identify innovative anticancer drugs that improve the current therapy either through novel combinatorial approaches or with better efficacy than conventional drugs. We aimed to provide an overview of the preclinical and clinical studies targeting key dysregulated signaling pathways in CRC as well as the therapeutic application of LNA-modified oligonucleotides, and miR inhibitors in the treatment of CRC patients. J. Cell. Biochem. 118: 4129-4140, 2017. © 2017 Wiley Periodicals, Inc.
|
Authors | Reza Nedaeinia, Amir Avan, Mehdi Ahmadian, Sasan Nedaee Nia, Maryam Ranjbar, Mohammadreza Sharifi, Mohammad Goli, Ahmad Piroozmand, Esmail Nourmohammadi, Mostafa Manian, Gordon A Ferns, Majid Ghayour-Mobarhan, Rasoul Salehi |
Journal | Journal of cellular biochemistry
(J Cell Biochem)
Vol. 118
Issue 12
Pg. 4129-4140
(12 2017)
ISSN: 1097-4644 [Electronic] United States |
PMID | 28401648
(Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
|
Copyright | © 2017 Wiley Periodicals, Inc. |
Chemical References |
- Antineoplastic Agents
- MIRN21 microRNA, human
- MicroRNAs
- Oligonucleotides
- locked nucleic acid
|
Topics |
- Adenocarcinoma
(drug therapy, metabolism)
- Animals
- Antineoplastic Agents
(pharmacology)
- Colorectal Neoplasms
(drug therapy, metabolism)
- Humans
- MicroRNAs
(antagonists & inhibitors)
- Oligonucleotides
(pharmacology)
- Signal Transduction
|